BRAIN Biotech (BNN) Stock Overview
Provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
BNN Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BRAIN Biotech AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.78 |
| 52 Week High | €3.89 |
| 52 Week Low | €2.05 |
| Beta | 0.62 |
| 1 Month Change | -2.11% |
| 3 Month Change | -4.14% |
| 1 Year Change | 26.94% |
| 3 Year Change | -37.25% |
| 5 Year Change | -72.09% |
| Change since IPO | -69.44% |
Recent News & Updates
Recent updates
Production Disruptions And Weak Margins Will Eventually Benefit Consolidated Enzyme Platform
Catalysts About BRAIN Biotech BRAIN Biotech AG is a European industrial biotechnology company that develops and produces enzyme based and bio based solutions for food, beverages and other industrial applications. What are the underlying business or industry changes driving this perspective?
Biological Solutions And Gene Editing Will Reshape Industrial Processes Over The Next Decade
Catalysts About BRAIN Biotech BRAIN Biotech develops and produces enzyme and microbial solutions for industrial and pharmaceutical applications. What are the underlying business or industry changes driving this perspective?Analysts Have Been Trimming Their BRAIN Biotech AG (ETR:BNN) Price Target After Its Latest Report
It's shaping up to be a tough period for BRAIN Biotech AG ( ETR:BNN ), which a week ago released some disappointing...Market Cool On BRAIN Biotech AG's (ETR:BNN) Revenues Pushing Shares 28% Lower
BRAIN Biotech AG ( ETR:BNN ) shares have retraced a considerable 28% in the last month, reversing a fair amount of...It's A Story Of Risk Vs Reward With BRAIN Biotech AG (ETR:BNN)
With a median price-to-sales (or "P/S") ratio of close to 0.6x in the Chemicals industry in Germany, you could be...Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...A Piece Of The Puzzle Missing From BRAIN Biotech AG's (ETR:BNN) 38% Share Price Climb
BRAIN Biotech AG ( ETR:BNN ) shares have had a really impressive month, gaining 38% after a shaky period beforehand...Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 27% Bounce
BRAIN Biotech AG ( ETR:BNN ) shares have continued their recent momentum with a 27% gain in the last month alone. Not...Further Upside For BRAIN Biotech AG (ETR:BNN) Shares Could Introduce Price Risks After 50% Bounce
BRAIN Biotech AG ( ETR:BNN ) shares have had a really impressive month, gaining 50% after a shaky period beforehand...BRAIN Biotech AG (ETR:BNN) Screens Well But There Might Be A Catch
With a median price-to-sales (or "P/S") ratio of close to 0.7x in the Chemicals industry in Germany, you could be...Is BRAIN Biotech (ETR:BNN) Weighed On By Its Debt Load?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...BRAIN Biotech AG (ETR:BNN) Shares Could Be 36% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, BRAIN Biotech fair value estimate is €4.43 Current share price...BRAIN Biotech AG's (ETR:BNN) P/S Still Appears To Be Reasonable
When close to half the companies in the Chemicals industry in Germany have price-to-sales ratios (or "P/S") below 0.7x...Is BRAIN Biotech (ETR:BNN) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Here's Why BRAIN Biotech (ETR:BNN) Can Afford Some Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Shareholder Returns
| BNN | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | -0.4% | -0.5% | -1.1% |
| 1Y | 26.9% | 16.1% | 3.3% |
Return vs Industry: BNN exceeded the German Chemicals industry which returned 16.3% over the past year.
Return vs Market: BNN exceeded the German Market which returned 4.7% over the past year.
Price Volatility
| BNN volatility | |
|---|---|
| BNN Average Weekly Movement | 6.9% |
| Chemicals Industry Average Movement | 3.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 12.0% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: BNN has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BNN's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 280 | Aryan Moelker | www.brain-biotech.com |
BRAIN Biotech AG provides bio-based products and solutions in Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two segments: BRAINBiocatalysts and BRAINBioIncubator. The BRAINBiocatalysts segment develops, produces, and distributes specialty enzymes, microorganisms, and ingredients.
BRAIN Biotech AG Fundamentals Summary
| BNN fundamental statistics | |
|---|---|
| Market cap | €60.74m |
| Earnings (TTM) | -€13.97m |
| Revenue (TTM) | €46.08m |
Is BNN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNN income statement (TTM) | |
|---|---|
| Revenue | €46.08m |
| Cost of Revenue | €19.66m |
| Gross Profit | €26.42m |
| Other Expenses | €40.39m |
| Earnings | -€13.97m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Jan 14, 2027
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 57.34% |
| Net Profit Margin | -30.33% |
| Debt/Equity Ratio | 0% |
How did BNN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/18 19:00 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BRAIN Biotech AG is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yi-Dan Wang | Deutsche Bank |
| Jan Koch | Deutsche Bank |
| Thomas Schießle | EQUI.TS GmbH |